These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 6107263)

  • 21. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.
    Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
    Gut; 1988 May; 29(5):669-74. PubMed ID: 2899536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis.
    Willoughby CP; Cowan RE; Gould SR; Machell RJ; Stewart JB
    Scand J Gastroenterol Suppl; 1988; 148():40-4. PubMed ID: 2906476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Long-term therapy in ulcerative colitis and Crohn's disease].
    Malchow H
    Fortschr Med; 1979 Aug; 97(29):1253-60. PubMed ID: 457018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition.
    Hetzel DJ; Shearman DJ; Labrooy J; Bochner F; Imhoff DM; Gibson GE; Fitch RJ; Hecker R; Rowland R
    Scand J Gastroenterol Suppl; 1988; 148():61-9. PubMed ID: 3067339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity.
    Aparicio-Pagés MN; Verspaget HW; Hafkenscheid JC; Crama-Bohbouth GE; Peña AS; Weterman IT; Lamers HW
    Gut; 1990 Sep; 31(9):1030-2. PubMed ID: 1976576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine.
    Allgayer H; Eisenburg J; Paumgartner G
    Eur J Clin Pharmacol; 1984; 26(4):449-51. PubMed ID: 6428914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study.
    Rao SS; Dundas SA; Holdsworth CD; Cann PA; Palmer KR; Corbett CL
    Gut; 1989 May; 30(5):675-9. PubMed ID: 2567266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolution of olsalazine.
    Truelove SC
    Scand J Gastroenterol Suppl; 1988; 148():3-6. PubMed ID: 2906475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical pharmacokinetics of sulphasalazine.
    Das KM; Dubin R
    Clin Pharmacokinet; 1976; 1(6):406-25. PubMed ID: 15752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group.
    Rutgeerts P
    Aliment Pharmacol Ther; 1989 Apr; 3(2):183-91. PubMed ID: 2577483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Unwanted side-effects in using mesalazine (5-aminosalicylic acid) during radiotherapy].
    Freund U; Schölmerich J; Siems H; Kluge F; Schäfer HE; Wannenmacher M
    Strahlenther Onkol; 1987 Oct; 163(10):678-80. PubMed ID: 3313776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study.
    Nilsson A; Danielsson A; Löfberg R; Benno P; Bergman L; Fausa O; Florholmen J; Karvonen AL; Kildebo S; Kollberg B
    Am J Gastroenterol; 1995 Mar; 90(3):381-7. PubMed ID: 7872274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The effect of sulphasalazine, sulphapyridine, 5-aminosalicylic acid and prednisolone on superoxide production by human polymorphonuclear leukocytes: in vitro studies].
    Ide T
    Nihon Shokakibyo Gakkai Zasshi; 1986 Sep; 83(9):2090. PubMed ID: 3025481
    [No Abstract]   [Full Text] [Related]  

  • 34. The scavenging of oxidants by sulphasalazine and its metabolites. A possible contribution to their anti-inflammatory effects?
    Aruoma OI; Wasil M; Halliwell B; Hoey BM; Butler J
    Biochem Pharmacol; 1987 Nov; 36(21):3739-42. PubMed ID: 2890355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sulphasalazine-induced reversible male infertility.
    Delaere KP; Strijbos WE; Meuleman EJ
    Acta Urol Belg; 1989; 57(1):29-33. PubMed ID: 2566274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis.
    Andreoli A; Spinella S; Levenstein S; Prantera C
    Ital J Gastroenterol; 1994 Apr; 26(3):121-5. PubMed ID: 7914759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Management of refractory and fulminating colitis].
    Turunen U
    Duodecim; 1987; 103(14):890-6. PubMed ID: 3328677
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and tolerance of mesalazine suppositories vs. hydrocortisone foam in proctitis.
    Lucidarme D; Marteau P; Foucault M; Vautrin B; Filoche B
    Aliment Pharmacol Ther; 1997 Apr; 11(2):335-40. PubMed ID: 9146772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sulphasalazine-induced leucopenia in a patient with renal dysfunction.
    Teshima D; Hino B; Makino K; Yano T; Itoh Y; Joh Y; Iida M; Oishi R
    J Clin Pharm Ther; 2003 Jun; 28(3):239-42. PubMed ID: 12795783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis.
    Kruis W; Judmaier G; Kayasseh L; Stolte M; Theuer D; Scheurlen C; Hentschel E; Kratochvil P
    Eur J Gastroenterol Hepatol; 1995 May; 7(5):391-6. PubMed ID: 7614099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.